Introduction Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ...

The DVLA advises you should tell them if you develop a 'notifiable' medical condition or disability, or if a condition has ...

Cardiac electrophysiology (EP) is a relatively young field. The first surgical ablation of an accessory pathway and the first ...

Background Fabry disease (FD) causes multiorgan sphingolipid accumulation, with cardiac involvement responsible for the ...

The Advanced Cardiac Institute in Raipur successfully performed the state’s first CRT-D device implantation for remote heart monitoring, revolutionizing care for patients with Sick Sinus Syndrome. The ...

Learn how LA stiffness index offers superior diagnostic accuracy in estimating LVFPs in acute heart failure, paving the way ...

Motorists are required to tell the DVLA about any medical conditions that could affect their driving or they could face a ...

BACKGROUND: Coagulation factor XI (FXI) inhibitors are a promising and novel class of anticoagulants, but a recent animal study found that FXI inhibition exacerbated diastolic dysfunction and heart ...

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible ...

Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, withTiered Royalties on Future Sales SOUTH SAN FRANCISCO, Calif. and ...

Tecarfarin has an orphan drug designation for left ventricular assist device (LVAD) patients and both orphan drug and fast-track designations for end-stage kidney disease patients with atrial ...

Using an artificial intelligence program to read echocardiograms may reduce the wait time for results and help lead to more ...